Topics: ADHD

Patients often come into my office to be “tested for ADHD,” and I explain to them that the diagnosis depends on a thorough clinical interview. Nonetheless, rating scales can be useful.

Topics: ADHD | Pharmaceutical Industry

In 2006, an FDA panel recommended all manufacturers of stimulants to add a “black box” warning about an increased risk of “serious cardiovascular events.”

To begin with, you have to specify whether you are thinking in terms of DSM-IV criteria or probable DSM-5 criteria. The major difference is that currently you have to establish that ADHD symptoms began before age seven, whereas DSM-5 is more lenient, requiring that they began by age 12.

Topics: Genetics and Psychiatry | Research Updates

For years, we have read articles about the promise of pharmacogenetic testing to help us choose and monitor medication treatment.

Topics: Research Updates | Women's Issues in Psychiatry

We know that the postpartum period is a risky time for women who have a history of depression, especially if they experienced postpartum depression in the past. But several questions about mood and pregnancy are still unanswered.

Topics: Antidepressants | Research Updates

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.